PROK
ProKidney Corp.
$1.66
-$0.05(-2.92%)
23
Overall
40
Value
10
Tech
21
Quality
Market Cap
$537.50M
Volume
883.98K
52W Range
$0.54 - $7.13
Target Price
$5.50
Company Overview
| Mkt Cap | $537.50M | Price | $1.66 |
| Volume | 883.98K | Change | -2.92% |
| P/E Ratio | -7.8 | Open | $1.72 |
| Revenue | $893.0K | Prev Close | $1.71 |
| Net Income | $-69.0M | 52W Range | $0.54 - $7.13 |
| Div Yield | N/A | Target | $5.50 |
| Overall | 23 | Value | 40 |
| Quality | 21 | Technical | 10 |
No chart data available
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. founded in 2015 and is based in Winston-Salem, North Carolina.
Latest News
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial
TipRanks Auto-Generated Newsdesk•a day ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PROK | $1.66 | -2.9% | 883.98K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |